# NRX-1074 in Early Course Schizophrenia

> **NCT02603458** · PHASE2 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** NRX-1074
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02603458
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2020-08
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn by the sponsor.
- **Last updated:** 2016-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603458, "NRX-1074 in Early Course Schizophrenia". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02603458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*